This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Back to overview

André Bergman group


André Bergman

Group Leader

Personal details


André Bergman studied Medicine and Biology at the VU University in Amsterdam. In 2002 he obtained his PhD from the same university (Prof H Pinedo and Prof G Peters). During his PhD he studied the mechanisms of resistance to the anti-cancer deoxynucleoside gemcitabine. Part of this research was done at Yale University, New Haven, USA. From 1999 on he was trained in Internal Medicine at the University of Utrecht and subsequently as a Medical Oncologist at VU University in Amsterdam. After being registered as a Medical Oncologist, he received a fellowship from the Dutch Cancer Society (KWF). During this fellowship he worked one year in the lab of Prof A Berns at the Netherlands Cancer Institute and one year in the lab of Prof W Nelson, Sidney Kimmel Cancer Center, Johns Hopkins Medical Institutions, Baltimore, USA. Since 2008 he works as a Medical Oncologist at the Antoni van Leeuwenhoek hospital, with a special interest in treating urogenital cancers. After receiving a personal grant from KWF in 2009, a research group was formed exploring the role of the microenvironment in prostate cancer development.

Share this page